This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Frank E. Young, MD, PhD; Stuart L. Nightingale, MD

JAMA. 1988;260(2):224-225.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

WE HEREIN describe two new investigational drugs, cytomegalovirus immune globulin and trimetrexate glucuronate, that physicians may obtain under treatment protocols for certain patients with the serious or life-threatening conditions for which the drugs are indicated. The drugs have been approved for early availability under special "Treatment IND" procedures by the commissioner of the Food and Drug Administration.

CYTOMEGALOVIRUS IMMUNE GLOBULIN

Background

Cytomegalovirus immune globulin (CMVIG), the subject of a Treatment IND, is sponsored by the Massachusetts Public Health Biologic Laboratories, Division of the State Laboratory Institute, Department of Public Health, The Commonwealth of Massachusetts, Boston. The product is indicated for the attenuation of primary cytomegalovirus (CMV) disease associated with kidney transplantation in seronegative recipients of kidneys from seropositive donors. Approximately 75% of untreated seronegative recipients would be expected to develop CMV infection.¹ Clinical studies have shown a 50% reduction in primary CMV disease in renal transplant recipients given CMVIG. . . . [Full Text PDF of this Article]

Author Affiliations
From the Food and Drug Administration, Rockville, Md.

Footnotes
Reprint requests to Office of Health Affairs, Room 14-95, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857 (Dr Nightingale).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?